浙江嘉善選用諾輝健康常衞清進行5萬户籍居民早篩
格隆匯5月30日丨據嘉善縣衞生健康局公眾號推文,2023年嘉善縣民生實事項目之一的慢病早防早篩干預項目即將於6月啟動。項目內容之一就是對全縣45-54週歲的5萬户籍居民免費進行無創多靶點基因腸癌早期篩查,通過檢測糞便中腸道細胞的基因變異情況聯合便潛血檢測,來判斷是否存在結直腸癌或癌前病變的風險。跟傳統的腸癌早期篩查手段相比,常衞清檢測無創、無痛,非侵入,“檢測大便隱血(FIT)、KRAS基因位點突變和NDRG4、BMP3基因甲基化,基因位點全部根據中國人羣基因組特徵選擇,通過自主研發的邏輯迴歸數學模型綜合得出檢測結果。該技術可以檢測出直徑1釐米以上進展期腺瘤和腸癌病灶,檢測性能為腸癌靈敏度95.5%,腺瘤靈敏度65.5%,特異性87.1%,陰性預測值達到99.6%。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.